On Topic Virtual Roundtable: EGFR Mutant Metastatic NSCLC - Updates on Testing, Treatment, Adverse Event Management, and Patient Education
Released On
March 28, 2023
Expires On
March 28, 2024
Media Type
Internet
Completion Time
60 minutes
Specialty
Education, Hematology-Oncology, Pulmonology
Topic(s)
Lung Cancer, Oncology
This activity is jointly provided by Postgraduate Institute for Medicine and Bio Ascend.
This activity is supported by an independent educational grant from Boehringer Ingelheim.
Credit Available
- Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)™
All other healthcare professionals completing this course will be issued a statement of participation.
Program Overview
Clinicians need expert guidance for the use of existing EGFR mutant-targeted agents safely and effectively, as well as planning for optimal integration of new agents and indications into practice when they become available. This online roundtable discussion will aim to provide healthcare providers with clinical recommendations to address existing and new therapy options for patients with NSCLC.
Target Audience
The target audience for this activity is community and academic medical oncologists, pulmonologists, allied health professionals, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with EGFR-altered NSCLC.
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Assess current testing guidelines for patients diagnosed with metastatic NSCLC, including recommendations for EGFR and MET testing
- Evaluate current therapies available for patients with NSCLC that harbor EGFR mutations and alterations, including safety and efficacy results from pivotal clinical trials
- Identify mitigation strategies to combat treatment-related adverse events that may occur with the use of EGFR-directed therapies, and educate patients and caregivers regarding these adverse events
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Bio Ascend. Postgraduate Institute for Medicine is jointly accredited by the American Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Topics of Discussion:
Module 1: Testing guidelines for patients with metastatic NSCLC
Module 2: Treating patients with EGFR mutant NSCLC
Module 3: Adverse event management strategies
Module 4: Patient/caregiver education
Method of Participation
There are no fees for participating in and receiving CME credit for this activity. During the accredited period, participants must: 1) read the educational objectives and faculty disclosures; 2) study the educational activity; 3) complete the pre- and post-test and evaluation.
Participants who complete the educational activity, pre- and post-test, and evaluation will receive a certificate of credit.
Disclosures of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:
Faculty
Anne Tsao, MD (Moderator)
Vice President, Academic Affairs
Professor, Thoracic/Head and Neck Medical Oncology
Director, Mesothelioma Program
MD Anderson Cancer Center
Houston, Texas
Grant/Research Support: Ariad, Astra Zeneca, BMS, Boehringer-Ingelheim, Eli Lilly, Epizyme, Genetech, Merck, Millennium, Novartis, Polaris, Seattle Genetics
Consultant/Advisory Board: Ariad, AstraZeneca, BMS, Boehringer-Ingelheim, Eli Lilly, EMD Serono, Genentech, GSK, Merck, Novartis, Pfizer, Roche, Seattle Genetics
Meghan Mooradian, MD
Instructor, Medicine, Harvard Medical School
Clinical Oncologists, Medical Oncology
Massachusetts General Hospital
Boston, Massachusetts
Speakers’ Bureau, Honoraria for non-CME: Bristol Myers Squibb
Consultant/Advisory Board: AstraZeneca, Bristol Myers Squibb, Xilio Therapeutics, Istari Oncology
Kelly Goodwin, MSN, RN, ANP-BC
Adult Care Nurse Practitioner
Massachusetts General Hospital
Boston, Massachusetts
No financial relationships to disclosures
Ivy Elkins
Lung Cancer Patient and Advocate
Co-Founder EGFR Resisters
Consultant/Advisory Board: AstraZeneca, Bayer, Blueprint, Boehringer Ingelheim, BMS, Daiichi, Gilead, Janssen, Merck, Mirati
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Course Viewing Requirements
Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Contact Information
For CME questions please contact: info@bioascend.com.